Key statistics
On Friday, Exelixis Inc (EX9:FRA) closed at 35.60, 21.05% above the 52 week low of 29.41 set on Oct 21, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 35.60 |
|---|---|
| High | 35.60 |
| Low | 35.60 |
| Bid | 36.46 |
| Offer | 37.75 |
| Previous close | 36.98 |
| Average volume | 88.50 |
|---|---|
| Shares outstanding | 259.71m |
| Free float | 253.47m |
| P/E (TTM) | 15.78 |
| Market cap | 11.41bn USD |
| EPS (TTM) | 2.78 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 07:16 GMT.
More ▼
Press releases
- Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
- Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
- Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
- Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
- Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
More ▼
